Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group: transgender men | Experimental |
| |
| Groupe: control cis-gender women | No Intervention | ||
| Group: transgender women | Experimental |
| |
| Groupe: control cis-gender men | No Intervention |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| gender affirming hormonal treatment in transgender men | Drug | testosterone enanthate |
|
| Measure | Description | Time Frame |
|---|---|---|
| pulse wave velocity | measurement of arterial stiffness | 24 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
yes
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014189 | Transsexualism |
| ID | Term |
|---|---|
| D019529 | Sexuality |
| D012725 | Sexual Behavior |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| gender affirming hormonal treatment in transgender women | Drug | GnRH agonists + estrogen |
|